Editas Medicine Inc. (NASDAQ:EDIT)’s share price was up 3.3% on Thursday . The stock traded as high as $19.43 and last traded at $18.95, with a volume of 143,067 shares changing hands. The stock had previously closed at $18.35.

Several equities analysts recently weighed in on EDIT shares. Zacks Investment Research downgraded Editas Medicine from a “hold” rating to a “sell” rating in a research report on Monday, August 15th. Jefferies Group assumed coverage on Editas Medicine in a report on Thursday, June 2nd. They set a “hold” rating and a $35.00 price target on the stock. Vetr raised Editas Medicine from a “hold” rating to a “buy” rating and set a $32.50 price target on the stock in a report on Monday, May 9th. Finally, Cowen and Company reissued a “buy” rating on shares of Editas Medicine in a report on Monday, May 16th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Editas Medicine presently has a consensus rating of “Buy” and a consensus price target of $33.50.

The stock’s market cap is $648.96 million. The stock has a 50 day moving average of $23.30 and a 200 day moving average of $29.15.

Editas Medicine (NASDAQ:EDIT) last released its earnings results on Tuesday, August 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.54). Equities analysts anticipate that Editas Medicine Inc. will post ($2.59) EPS for the current fiscal year.

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.